Filing Flows › Bionano Genomics (BNGO) › Q1 2025
Bionano Genomics (BNGO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
Bionano Genomics (BNGO) reported revenue of $6.5M for the first quarter 2025 (Q1 2025), -26% from a year earlier and -21% from the quarter before. Operating margin was -131.1%, net loss $3.1M (48.0% of revenue).
Bionano Genomics, Q1 2025: revenue $6.5M (-26% year over year), operating margin -131.1%, net loss $3.1M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.5M | -21% | -26% |
| Operating profit | −$8.5M | — | — |
| Net earnings | −$3.1M | — | — |
| Operating cash flow | −$2.8M | — | — |
What changed
Revenue was $6.5M in Q1 2025, down 26% year over year and down 21% from the previous quarter. Consumables was the largest line at 50% of revenue. Service and other revenue lost $1.5M year over year (down 77%), 64% of the total change.
Operating costs exceeded revenue by $8.5M, an operating margin of -131.1%. Total costs fell 63% while revenue fell 26%. The quarter ended with a net loss of $3.1M, narrower than the previous quarter's $20.1M loss. Non-operating items added $5.4M, -174% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.8M. Non-cash charges added back $2.4M of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $3.7M.
Questions
What was Bionano Genomics' revenue in the first quarter 2025?
Bionano Genomics (BNGO) reported revenue of $6.5M for the first quarter 2025 (Q1 2025), -26% from a year earlier and -21% from the quarter before.
Was Bionano Genomics profitable in the first quarter 2025?
Operating loss was $8.5M (-131.1% of revenue) and net loss $3.1M.
Source: Bionano Genomics 10-Q on SEC EDGAR.